Liat Halpert 2024-06-13 Liat Halpert 2024-06-13

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Olga Rosenman 2024-06-07 Olga Rosenman 2024-06-07

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders’ Equity Requirement.

Liat Halpert 2024-05-24 Liat Halpert 2024-05-24

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders’ Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

Liat Halpert 2024-05-16 Liat Halpert 2024-05-16

Scinai FY 2023 Financial Results and Business Update

Liat Halpert 2024-05-12 Liat Halpert 2024-05-12

Scinai Immunotherapeutics announces receipt of Nasdaq delisting notification and appeal

Liat Halpert 2024-04-10 Liat Halpert 2024-04-10

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Liat Halpert 2024-04-08 Liat Halpert 2024-04-08

Scinai Immunotherapeutics’ CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Josh Phillipson 2024-03-12 Josh Phillipson 2024-03-12

Scinai leadership to attend BIO-Europe Spring 2024

Josh Phillipson 2024-02-29 Josh Phillipson 2024-02-29

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

Josh Phillipson 2024-02-13 Josh Phillipson 2024-02-13

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Josh Phillipson 2024-01-25 Josh Phillipson 2024-01-25

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Josh Phillipson 2024-01-04 Josh Phillipson 2024-01-04

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Josh Phillipson 2024-01-02 Josh Phillipson 2024-01-02

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Josh Phillipson 2023-12-29 Josh Phillipson 2023-12-29

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Josh Phillipson 2023-12-27 Josh Phillipson 2023-12-27

Scinai (Nasdaq: SCNI) to Host Analyst and Investor Webinar on January 9

Josh Phillipson 2023-12-12 Josh Phillipson 2023-12-12

Scinai Announces Promising Results in a Psoriatic Human Skin Model

Josh Phillipson 2023-12-11 Josh Phillipson 2023-12-11

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics’ coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

Josh Phillipson 2023-11-29 Josh Phillipson 2023-11-29

European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031

Significant positive impact to Scinai’s financial health is expected

Amendment made in light of Scinai’s recent strategic shift to development of nanosized antibody therapeutics aimed at inflammation and immunology diseases

Josh Phillipson 2023-11-20 Josh Phillipson 2023-11-20

Scinai Immunotherapeutics Regains Compliance with Nasdaq’s Stockholders’ Equity Rule

Josh Phillipson 2023-11-06 Josh Phillipson 2023-11-06

Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit

PRESS RELEASES